title: Phosphatidylserine containing omega-3 Fatty acids may improve memory abilities in nondemented elderly individuals with memory complaints: results from an open-label extension study.
abstract: BACKGROUND
  The present study is an open-label extension (OLE) aimed at evaluating the effect of 100 mg/day of phosphatidylserine enriched with docosahexaenoic acid (PS-DHA) on cognitive performance in nondemented elderly individuals with memory complaints.
  
  
  METHODS
  From the participants who completed the core study, 122 continued with a 15-week OLE. Efficacy was assessed using a computerized tool and the Clinical Global Impression of Change (CGI-C) rating scale.
  
  
  RESULTS
  A significant improvement in sustained attention and memory recognition was observed in the PS-DHA naïve group, while the PS-DHA continuers maintained their cognitive status. Additionally, a significant improvement in CGI-C was observed in the naïve group.
  
  
  CONCLUSIONS
  The results demonstrate that consumption of 100 mg/day of PS-DHA might be associated with improving or maintaining cognitive status in elderly subjects with memory complaints.
authors.affiliation: Neurology Consultant, Maccabi Health Services, Tel Aviv, Israel.
authors.forename: Veronika
authors.initials: V
authors.lastname: Vakhapova
authors.forename: Tzafra
authors.initials: T
authors.lastname: Cohen
authors.forename: Yael
authors.initials: Y
authors.lastname: Richter
authors.forename: Yael
authors.initials: Y
authors.lastname: Herzog
authors.forename: Yossi
authors.initials: Y
authors.lastname: Kam
authors.forename: Amos D
authors.initials: AD
authors.lastname: Korczyn
mesh_terms: D000368:Aged; D001288:Attention / Q000187:drug effects*; D004281:Docosahexaenoic Acids / Q000008:administration & dosage / Q000009:adverse effects; D004338:Drug Combinations; D016903:Drug Monitoring; D005260:Female; D015577:Geriatric Assessment / Q000379:methods; D006801:Humans; D008297:Male; D008568:Memory / Q000187:drug effects*; D008569:Memory Disorders / Q000175:diagnosis / Q000188:drug therapy / Q000523:psychology; D009483:Neuropsychological Tests; D018697:Nootropic Agents / Q000008:administration & dosage / Q000009:adverse effects; D010718:Phosphatidylserines / Q000008:administration & dosage / Q000009:adverse effects; D011569:Psychiatric Status Rating Scales; D016896:Treatment Outcome
chemical_list: D004338:Drug Combinations; D018697:Nootropic Agents; D010718:Phosphatidylserines; D004281:Docosahexaenoic Acids